Inventurus Knowledge Solutions Limited has informed the Exchange regarding a press release dated May 15, 2025, titled "Press Release Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2025.".
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IKS Health, a technology-enabled healthcare solutions provider focused on the US market, reported strong Q4 FY25 results. Quarterly revenue grew 17% year-on-year to ₹7,240 million, while profit after tax (PAT) surged 133% YoY to ₹1,478 million. EBITDA rose 68% YoY to ₹2,262 million, with margins crossing 31% (up from 24% proforma in FY24). For the full year FY25, revenue reached ₹26,640 million (47% YoY), EBITDA ₹7,911 million (50% YoY), and PAT ₹4,861 million (31% YoY). The company won 5 new clients in Q4, including 3 platform deals (Sky Lakes, GI Alliance, Western Washington Medical Group), and received several industry recognitions including top honors in Black Book Research 2025 for AI-driven Revenue Cycle Management and Best in KLAS 2025 for Medical Transcription Services.
Very strong earnings beat with double-digit revenue growth, sharp profit acceleration, and meaningful margin expansion signal robust business momentum. The five client wins and industry-leading recognitions reinforce the company's competitive position and growth outlook, likely to be viewed positively by investors.